Myasthenia gravis in individuals over 40

Annals of the New York Academy of Sciences

Volumn 998, Issue , 2003, Pages 424-431

  Aarli, Johan A ^a,b   Romi, Fredrik ^a   Skeie, Geir Olve ^a   Gilhus, Nils Erik ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Acetylcholine receptor; Epidemiology; Myasthenia gravis; Ryanodine receptor; Thymoma; Thymus; Titin

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; CONNECTIN; RYANODINE RECEPTOR; TUMOR NECROSIS FACTOR;

ADULT; AGE DISTRIBUTION; AUTOIMMUNE DISEASE; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE DURATION; DNA POLYMORPHISM; EPIDEMIOLOGICAL DATA; HLA SYSTEM; HUMAN; IMMUNOLOGICAL MONITORING; MYASTHENIA GRAVIS; ONSET AGE; THYMOMA;

EID: 0141504279     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1254.055     Document Type: Conference Paper

References (34)

1. ERB, W. 1879. Zur Casuistik der bulbären Lähmungen. Über einen neuen, wahrscheinlich bulbären Symptomencomplex. Arch. Psychiatrie 9: 336-350.
2. CAMPBELL, H. & E. BRAMWELL. 1900. Myasthenia gravis. Brain 23: 277-366.
3. GOLDFLAM, S. 1893. Über einen scheinbar heilbaren bulbärparalytischen Symptomen-complex mit Betheiligung der Extremitäten. Dtsch. Z. Nervenheilkd. 4: 312-352.
4. LAQUER, L. 1903. Ueber die Erb'sche Krankheit (myasthenia gravis). Neurol. Zentralbl. 20: 594-597.
5. WEIGERT, C. 1903. Patologisch-anatomischer Beitrag zur Erb'schen Krankheit (myasthenia gravis). Neurol. Zentralbl. 20: 597-601.
6. SIMPSON, J.F., M.R. WESTERBERG & K.R. MAGEE. 1966. Myasthenia gravis: an analysis of 295 cases. Acta Neurol. Scand. 42(suppl. 23): 1-27.
7. SCHWAB, R.S. & C.C. LELAND. 1953. Sex and age in myasthenia gravis as critical factors in incidence and remission. J. Am. Med. Assoc. 153: 1270-1273.
8. OSSERMAN, K.E. & G. GENKINS. 1971. Studies in myasthenia gravis: a review of a twenty-year experience in over 1200 patients. Mt. Sinai J. Med. 38: 497-537.
9. STORM-MATHISEN, A. 1984. Epidemiology of myasthenia gravis in Norway. Acta Neurol. Scand. 70: 274-284.
10. CHRISTENSEN, P.B. et al. 1993. Incidence and prevalence of myasthenia gravis in western Denmark: 1975 to 1989. Neurology 43: 1779-1783.
11. OSTERMAN, P. 1990. Current treatment of myasthenia gravis. In Progress in Brain Research, pp. 151-161. Elsevier Science. Oxford.
12. SOMNIER, F.E., N. KEIDING & O.B. PAULSON. 1991. Epidemiology of myasthenia gravis in Denmark: a longitudinal and comprehensive population survey. Arch. Neurol. 48: 733-739.
13. COMPSTON, D.A.S. et al. 1980. Clinical, pathological, HLA-antigen, and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 103: 579-601.
14. DONALDSON, D.H. et al. 1990. The relationship of age to outcome in myasthenia gravis. Neurology 40: 786-790.
15. CHRISTENSEN, P.B. et al. 1995. Associated autoimmune diseases in myasthenia gravis: a population-based study. Acta Neurol. Scand. 91: 192-195.
16. CHRISTENSEN, P.B. et al. 1998. Mortality and survival in myasthenia gravis: a Danish population based study. J. Neurol. Neurosurg. Psychiatry 64: 78-83.
17. AARLI, J.A. 1994. Myasthenia gravis and thymoma. In Handbook of Myasthenia Gravis and Myasthenic Syndromes, pp. 207-224. Dekker. New York.
18. NEWSOM-DAVIS, J., A. VINCENT & N. WILLCOX. 1982. Acetylcholine receptor antibody: clinical and experimental aspects. In Receptors, Antibodies, and Disease. Ciba Foundation Symposium. Vol. 90, pp. 225-247. Pitman. London.
19. AARLI, J.A. 1997. Late onset myasthenia gravis. Eur. J. Neurol. 4: 203-209.
20. LIMBURG, P.C. et al. 1983. Anti-acetylcholine receptor antibodies in myasthenia gravis. I. Relation to clinical parameters in 250 patients. J. Neurol. Sci. 58: 357-370.
21. MANTEGAZZA, R. et al. 1998. Anti-AChR antibody: relevance to diagnosis and clinical aspects of myasthenia gravis. Ital. J. Neurol. Sci. 9: 141-145.
22. LINDSTROM, J.M. et al. 1976. Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. Neurology 26: 1054-1059.
23. ROMI, F. et al. 2000. Muscle autoantibodies in subgroups in myasthenia gravis patients. J. Neurol. 247: 369-375.
24. DRACHMAN, D.B. et al. 1982. Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N. Engl. J. Med. 307: 769-775.
25. AARLI, J.A. et al. 1990. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clin. Exp. Immunol. 82: 284-288.
26. GAUTEL, M. et al. 1993. Identification of a major immunogenic region of titin. Neurology 43: 1581-1585.
27. SKEIE, G.O. et al. 1995. Titin antibodies in patients with late onset myasthenia gravis: clinical correlations. Autoimmunity 20: 99-104.
28. YAMAMOTO, A.M. et al. 2001. Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients. Arch. Neurol. 58: 885-890.
29. MYGLAND, Å. et al. 1992. Ryanodine receptor autoantibodies in myasthenia gravis patients with thymoma. Ann. Neurol. 32: 589-591.
30. MYGLAND, Å. et al. 1994. Ryanodine receptor autoantibodies related to the severity of thymoma associated myasthenia gravis. J. Neurol. Neurosurg. Psychiatry 57: 843-846.
31. SKEIE, G.O. et al. 2001. Autoimmunity against the ryanodine receptor in myasthenia gravis. Acta Physiol. Scand. 171: 379-384.
32. SKEIE, G.O. et al. 1999. TNFA and TNFB polymorphism in myasthenia gravis. Arch. Neurol. 56: 457-461.
33. GIRAUD, M. et al. 2001. Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies. Neurology 57: 1555-1560.
34. ROMI, F. et al. 2002. Thymectomy and anti-muscle autoantibodies in late-onset myasthenia gravis. Eur. J. Neurol. 9: 55-61.